Discovery of potent and selective orally bioavailable β-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 12, 2005, Pages 3048-3052

  Edmondson, Scott D ^a   Mastracchio, Anthony ^a   Duffy, Joseph L ^a   Eiermann, George J ^a   He, Huaibing ^a   Ita, Ida ^a   Leiting, Barbara ^a   Leone, Joseph F ^a   Lyons, Kathryn A ^a   Makarewicz, Amanda M ^a   Patel, Reshma A ^a   Petrov, Aleksandr ^a   Wu, Joseph K ^a   Thornberry, Nancy A ^a   Weber, Ann E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Dipeptidyl peptidase IV; DPP IV; DPP8; DPP9; QPP

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; PHENYLALANINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; GLUCOSE BLOOD LEVEL; NONHUMAN; RAT; SUBSTITUTION REACTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; DNA-BINDING PROTEINS; GLUCOSE TOLERANCE TEST; HUMANS; MICE; MOLECULAR STRUCTURE; PHENYLALANINE; PROTEASE INHIBITORS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TRANS-ACTIVATORS;

EID: 19944416214     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.04.028     Document Type: Article

References (23)

1. For lead DPP-IV references, see: R. Mentlein Expert Opin. Invest. Drugs 14 2005 57
2. A.E. Weber J. Med. Chem. 47 2004 4135
3. C.F. Deacon Diabetes 53 2004 2181
4. C.F. Deacon, B. Ahren, and J.J. Holst Expert Opin. Invest. Drugs 13 2004 1091
5. J.J. Holst, and C.F. Deacon Curr. Opin. Pharmacol. 4 2004 589
6. For lead GLP-1 references, see: J.J. Holst Curr. Opin. Endocrin. Diabetes 12 2005 56
7. L.B. Knudsen J. Med. Chem. 47 2004 4128
8. T.P. Vahl, and D.A. D'Alessio Expert Opin. Invest. Drugs 13 2004 177
9. M.J. During, L. Cao, D.S. Zuzga, J.S. Francis, H.L. Fitzsimons, X. Jiao, R.J. Bland, M. Klugmann, W.A. Banks, D.J. Drucker, and C.N. Haile Nat. Med. 9 2003 1173
10. B. Ahren, M. Landin-Olsson, P.-A. Jansson, M. Svensson, D. Holmes, and A. Schweizer J. Clin. Endocrin. Metab. 89 2004 2078
11. Xu, J; Wei, L.; Mathvink, R.; He, J.; Park, Y.-J.; He, H.; Leiting, B.; Lyons, K. A.; Marsilio, F.; Patel, R. A.; Wu, J. K.; Thornberry, N. A.; Weber, A. E.; Parmee, E. R. Bioorg. Med. Chem. Lett. 2005, 15, 2533
12. 50 determinations for hERG was carried out as described in R.W. Friesen, Y. Ducharme, R.G. Ball, M. Blouin, L. Boulet, B. Cote, R. Frenette, M. Girard, D. Guay, Z. Huang, T.R. Jones, F. Laliberte, J.J. Lynch, J. Mancini, E. Martins, P. Masson, E. Muise, D.J. Pon, P.K.S. Siegel, A. Styhler, N.N. Tsou, M.J. Turner, R.N. Young, and Y. Girard J. Med. Chem. 46 2003 2017
13. E.J. Corey, and C.J. Helal Tetrahedron Lett. 36 1995 9153
14. E.J. Corey, and C.J. Bakshi Tetrahedron Lett. 31 1990 611
15. U. Kazmaier Liebigs Ann. Recl. 1997 285
16. U. Kazmaier Angew. Chem., Int. Ed. Engl. 33 1994 998
17. C.G. Caldwell, P. Chen, J. He, E.R. Parmee, B. Leiting, F. Marsilio, R.A. Patel, J.K. Wu, G.J. Eiermann, A. Petrov, H. He, K.A. Lyons, N.A. Thornberry, and A.E. Weber Bioorg. Med. Chem. Lett. 14 2004 1265
18. 1H NMR and LC-MS
19. 50 determinations for DPP-IV and other proline peptidases were carried out as described in B. Leiting, K.D. Pryor, J.K. Wu, F. Marsilio, R.A. Patel, C.S. Craik, J.A. Ellman, R.T. Cummings, and N.A. Thornberry Biochem. J. 371 2003 525
20. 1 position of dipeptide α-amino amide inhibitors has been investigated with DPP-IV and QPP (DPP-II). For a lead reference, see: K. Senten, P.V. Veken, I. De Meeser, A.-M. Lambeir, S. Scharpe, A. Haemers, and K. Augustyns J. Med. Chem. 46 2003 5005
21. G. Lankas, B. Leiting, R. Sinha Roy, G. Eiermann, T. Biftu, D. Kim, H. Ok, A.E. Weber, and N.A. Thornberry Diabetes 53 2004 A2
22. 50's against human calcium and sodium channels were also measured, and activity at hERG is indicative of activity at these other ion channels
23. It should be noted that the % inhibition as determined using the in vitro assay underestimates the % inhibition achieved in vivo, since compound 22 is a competitive, reversible inhibitor and the assay of plasma DPP-IV activity requires dilution of plasma (resulting in dilution of the total inhibitor) and the presence of substrate that competes with inhibitor for binding to the enzyme